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Abstract
A collection of swine, fish, and cetacean Erysipelothrix rhusiopathiae strains representing 16 serotypes was
analyzed for possession of the three currently recognized surface protective antigen (spa)-types: spaA, spaB,
and spaC. Polymerase chain reaction (PCR) assays and Western blotting with a SpaA-specific monoclonal
antibody demonstrated that spa-type is not confined to specific serotype groups. In particular, the spa-type of
strains of aquatic origin was more variable than those of terrestrial origin, and possessed the distinct ability to
express more than one spa. In a cross-protection study, mice immunized with an E. rhusiopathiae serotype 2
SpaA-type strain and challenged with various E. rhusiopathiae isolates were completely protected against
strains exhibiting a single homologous spa, but variably protected against strains possessing a heterologous spa
or those harboring more than one spa-type.
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a b s t r a c t
A collection of swine, ﬁsh, and cetacean Erysipelothrix rhusiopathiae strains representing 16 serotypes
was analyzed for possession of the three currently recognized surface protective antigen (spa)-types:
spaA, spaB, and spaC. Polymerase chain reaction (PCR) assays and Western blotting with a SpaA-speciﬁc
monoclonal antibodydemonstrated that spa-type isnot conﬁned to speciﬁc serotypegroups. Inparticular,
the spa-type of strains of aquatic origin was more variable than those of terrestrial origin, and possessed
the distinct ability to express more than one spa. In a cross-protection study, mice immunized with an
E. rhusiopathiae serotype 2 SpaA-type strain and challenged with various E. rhusiopathiae isolates were
completely protected against strains exhibiting a single homologous spa, but variably protected against
strains possessing a heterologous spa or those harboring more than one spa-type.
Published by Elsevier Ltd.
1. Introduction
Erysipelothrix rhusiopathiae is a bacterial organismwhich causes
erysipelas in a variety of mammals and birds, as well as erysipeloid
in humans [1]. Erysipelas is commonly associated with swine, and
is characterized by urticarial diamond-shaped lesions which can
quickly progress to an acute septicemic infection or death. Chronic
erysipelas usually follows an acute infection where self-sustaining,
destructive pathological changes in the heart valves and joints pro-
duce endocarditis and arthritis, respectively [1]. The disease has
recently reemerged in the Midwestern United States [2] but also
has an economic and epidemiological impact on animal produc-
tion and handling worldwide. While outbreaks of the disease are
reported most often in swine and turkeys, cetaceans are also com-
monly affected.
The genus Erysipelothrix contains two accepted species, E. rhu-
siopathiae which include serotypes 1a, 1b, 2, 4, 5, 6, 8, 9, 11, 12,
15, 16, 17, 19, 21 and N; E. tonsillarum containing serotypes 3, 7,
10, 14, 20, 22 and 23 [3,4]. Two unclassiﬁed Erysipelothrix groups
representing serotypes 13 and 18 are also recognized [4]. E. rhu-
siopathiae is considered to be the pathogenic specie of the genus
[5], and killed and attenuated live vaccines are used to prevent dis-
ease. Bacterins for the prevention of swine erysipelas are composed
∗ Corresponding author. Tel.: +1 515 337 7655; fax: +1 515 337 7673.
E-mail address: Alaina.L.Ingebritson@aphis.usda.gov (A.L. Ingebritson).
of serotype 2 strains [1] which provide effective cross-protection
against serotypes 1a, 1b, and 2 [6,7], the most relevant serotypes of
swine and turkey erysipelas [1,8]. These bacterin formulations also
protect against other E. rhusiopathiae serotypes, but often to a lesser
degree [6,7,9]. Marine aquaria also rely on swine strain bacterins
to protect against cetacean erysipelas [10,11]; however, complete
protection is not always attained [11].
The 64–66kilodalton (kDa) cell surface protein of E. rhu-
siopathiae is responsible for eliciting highly protective antibodies
[12–14], and is considered to be the major immunogenic antigen
of the specie [15]. The gene encoding the protective 64–66kDa
protein was ﬁrst sequenced by Makino et al. [16] who named it,
surface protective antigen A (spaA). Recently, two additional types
of spa-related genes were detected within E. rhusiopathiae and an
unclassiﬁed serotype18of the genus Erysipelothrix [17]. Amino acid
sequence analysis determined that serotypes 1a, 1b, 2, 5, 8, 9, 12,
15, 16, 17 and N possess spaA; serotypes 4, 6, 11, 19 and 21 possess
spaB; and the unclassiﬁed serotype 18 possesses spaC [17].
The three molecular groups are distinguished by amino acid
sequence and are considered antigenically distinct [17]. In active
immunization experiments in mice, recombinant Spa antigens
were completely protective against virulent E. rhusiopathiae strains
possessing homologous spa [17,18], but variably protective against
strains possessing heterologous spa-types [17].
In this study, we evaluated a variety of swine, ﬁsh, and cetacean
E. rhusiopathiae strains representing all 16 serotypes, and found
that spa-type is not conﬁned to speciﬁc serotype groups. We then
0264-410X/$ – see front matter Published by Elsevier Ltd.
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analyzed the ability of a bacterin, formulated with an E. rhu-
siopathiae serotype2 strain expressing spaA, toprotectmice against
a variety of cetacean and ﬁsh isolates of known Spa-type.
2. Materials and methods
2.1. Bacterial strains, growth conditions, and challenge
preparation
E. rhusiopathiae strains used in this study are listed in Table 1
. E. rhusiopathiae strains from R.L. Wood were serotyped at the
USDA National Animal Disease Center or National Veterinary Ser-
vices Laboratories (Ames, IA) andﬁsh and cetacean strains obtained
from the John G. Shedd Aquarium (Chicago, IL) were serotyped at
theVeterinaryDiagnostic Laboratory, Iowa StateUniversity College
of Veterinary Medicine (Ames, IA).
Cultures were streaked for isolation and grown on 5% bovine
blood agar at 37 ◦C and propagated as previously documented [17].
Strains used for testing inmicewere Piquet, Immiayuk, Quitz, Nalu-
ark, Kayavak, Large Herring 182, and Large Herring 911. Overnight
cultures were adjusted to 74.0%T±0.2 in a spectrophotometer set
at 600nm prior to preparing dilutions for injection in mice.
2.2. PCR ampliﬁcation
Genomic DNA of E. rhusiopathiae strains was puriﬁed from
1.0mL of overnight culture using QIAamp® DNA Mini Kit (Qiagen,
Valencia, CA). The following primers were designed from the pro-
tective domain of spaA of E. rhusiopathiae strain Fujisawa (GenBank
accession AB019124) using Oligo 6 software (Molecular Biology
Insights, Inc., Cascade, CO) and custom synthesized (Iowa State
University DNA Facility, Iowa State University, Ames, IA): spaA2F,
5′-CCA AAGGGG TAC CAAAGT T-3′, corresponding to position 259-
277, and spaA2R, 5′-GAT TCG GGT TTT GAT TGA-3′, corresponding
to position 1328-1311. Polymerase chain reaction was performed
in a 50L reaction mixture that contained ﬁnal concentrations of
one unit Platinum® TaqDNApolymerase (Invitrogen, Carlsbad, CA),
1× reaction buffer, 1.5mM MgCl2, 0.2mM dNTPs, and 0.2M each
primer. Samples were subjected to initial denaturation at 94◦ C for
5min; 30 cycles of denaturation at 94 ◦C for 30 s, annealing at 58 ◦C
for 30 s, and extension at 72 ◦C for 1min; with a ﬁnal extension at
72 ◦C for 7min.
The following primers were synthesized (Iowa State Univer-
sity DNA Facility) and used in PCR assays according to previously
described reports: primer 1, 5′-ATG AAA AAG AAA AAA CAC CTA-3′,
and primer 2, 5′-CTA TTT TAA ACT TCC ATC GTT-3′, were used to
amplify whole spaA [17]; primer 3, 5′-ATG AAA AAG AAA AAA CAC
CTA TTT CCG AAA GTA-3′, and primer 4, 5′-CTA TTT TAA ACT TCC
ATC GTT CTT AAA TGC ATA-3′, were used to amplify whole spaB
or spaC [17]; ERY-1F, 5′-ATC GAT AAA GTG TTA TTG GTG G-3′, and
ERY-2R, 5′-CGA GTG TGA ATC CGT CGT CTC-3′, were used to verify
the species of Erysipelothrix strains [19].
2.3. Sequencing of the spa protective domain
A 1070base pair (bp) fragment of the protective domain of
spaA from genomic DNA of E1-6P, Immiayuk, Piquet, Large Her-
ring 182, and Large Herring 911 was ampliﬁed by PCR with primer
set spaA2F/R. The PCR product from each strain was puriﬁed
using the MinElute® PCR puriﬁcation kit (Qiagen) and inserted
into the cloning vector pCR®4-TOPO® (Invitrogen) and transfected
into OneShot® TOP10 chemically competent Escherichia coli (Invit-
rogen) following the manufacturer’s instructions. Plasmids were
puriﬁed using the PureLinkTM Quick Plasmid Miniprep kit (Invitro-
gen). Both strands of DNA of cloned PCR products were sequenced
on a Model 3730xl DNA Analyzer (Applied Biosystems, Carls-
bad, CA) using a primer-walking procedure starting with vector
primers T3 and T7. DNA sequences were assembled using the
SeqMan program of the DNASTAR software package (DNASTAR
Inc., Madison, WI) and translated into amino acid sequence using
EMBOSS Transeq [20]. Amino acid sequences were aligned with
Spa sequences of E. rhusiopathiae strains Fujisawa (GenBank acces-
sion AB019124), SE-9 (AB024084), Dolphin E-1 (AB238212), and
Erysipelothrix strain 715 (AB238210) using the T-Coffee multiple
sequence alignment tool [21].
2.4. Antigen and antibody preparation
Surface antigens of E. rhusiopathiae were obtained by extraction
with Triton X-100 (Sigma–Aldrich, Inc., St. Louis, MO) as previously
described [12,14] and stored at −80 ◦C.
Themonoclonal antibody ERHU-B60-91was produced by vacci-
nating mice with a bacterin composed of E. rhusiopathiae serotype
2 strains SE-9, CN 3461, CN 3342, and AN-4 as previously described
[22]. The antibody has been shown to be speciﬁc for the protective
domain of SpaA (data not shown).
2.5. SDS-PAGE and Western blot
Total protein of each E. rhusiopathiae antigen preparation
was estimated using the BCATM Protein Assay (Thermo Scien-
tiﬁc, Rockford, IL). Approximately 50g of protein per sample
per well was separated in NuPAGE® Novex Bis-Tris 4–12% gradi-
ent gels (Invitrogen) in MOPS buffer under reducing conditions.
Separated proteins were transferred to nitrocellulose mem-
branes and blocked in 20mM Tris—500mM NaCl—0.5% Tween
20 (TTBS, pH 7.5). The proteins were probed with the SpaA-
speciﬁc monoclonal antibody, ERHU-B60-91 [1,22], and visualized
withgoat-anti-mouse IgG-horseradishperoxidase conjugatedanti-
body (Kirkegaard and Perry Laboratories, Gaithersburg, MD)
and 3,3′,5,5′-tetramethylbenzidine (TMB) and TMB Membrane
Enhancer (Kirkegaard and Perry Laboratories) substrate solution.
Separated total protein of each sample was visualized by
staining duplicate SDS-PAGE gels with SimplyBlueTM SafeStain
(Invitrogen) or by staining duplicate nitrocellulose membranes
with AuroDyeTM Forte (GE Healthcare, Buckinghamshire, UK).
2.6. Animals
CF-1 mice (Charles River Laboratories, Wilmington, MA) 8–10
weeks old were used for each experiment. Mice were provided
food and water ad libitum. All management and experimental pro-
cedures were performed in accordance with the requirements of
the USDA Center for Veterinary Biologics-National Veterinary Ser-
vices Laboratory Animal Care and Use Committee which conform
to provisions of the Animal Welfare Act (Public Laws 85-544 and
subsequent amendments).
2.7. Erysipelothrix rhusiopathiae strain lethality testing
The mouse 50% lethal dose (LD50) of each E. rhusiopathiae strain
wasdeterminedby inoculatinggroupsofmice subcutaneouslywith
0.1mL of a 10-fold dilution of overnight culture. Mice were housed
in isolation andobserved for 10days for clinical signs andmortality.
The LD50 was calculated for each strain following the method of
Reed and Muench [23].
2.8. Cross-protection studies
A working stock of E. rhusiopathiae standard reference bacterin
IRP 529(05) was prepared in sterile 0.85% saline as recommended
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Table 1
Erysipelothrix rhusiopathiae strains and PCR and Western blotting results.
Strain Serotype ERY1F/2R Primer 1/2 spaA2F/R Primer 3/4 ERHU-B6091
185–204g 1a Y Y Y
Fujisawaf,h 1a Y Y Y Y
Marienfeldeg 1a Y Y Y
Kuniyasug 1a Y Y Y
ME-7c,g 1a Y Y Y
E1-6Pf,g 1a Y Y Y O Y
HC-585g 1a Y Y Y
Hydrovace,g 1a Y Y Y
DG 1534g 1b Y Y Y
EW-2g 1b Y Y Y
DG 1966 spg 1b Y Y Y
422-1E1c,h 1b Y Y Y
Norden 141e,g 2 Y Y Y
R32E11g 2 Y Y Y
FDvace,g 2 Y Y Y
J80 smoothg 2 Y Y Y
10-4g 2 Y Y Y
RO-12g 2 Y Y Y
R-2 Frankling 2 Y Y Y
T-28g 2 Y Y Y
CN 3342e,g 2 Y Y Y
CN 3461e,g 2 Y Y Y
266g 2 Y Y Y
Duragene,g 2 Y Y Y
Yena-36g 2 Y Y Y
A1 Japang 2 Y Y Y
AN-4e,g 2 Y Y Y
S-192g 2 Y Y Y
ER4g 2 Y Y Y
ER5g 2 Y Y Y
SE-9e,g 2 Y Y Y Y
ATCC 19414d,h 2 Y Y Y
NF4E1c,h 2 Y Y Y
Doggerscharbei 4 Y O O O O
748g 4 Y O O O O
Pécs 67c,h 5 Y Y Y
P-190g 5 Y Y Y
Castro S66g 5 Y O O O O
Castro P23g 5 Y O O O O
Castro S52g 6 Y O O O O
P32g 6 Y O O O O
Tuzokc,j 6 Y O O O O
V1227g 8 Y Y Y
Godac,j 8 Y Y Y
P92g 8 Y O O O O
P26g 8 Y O O O O
Kaparekc,i 9 Y Y Y
IV 12/8c,h 11 Y O O O O
Pécs 52g 11 Y O O O O
Pécs 9c,h 12 Y Y Y
Castro S61g 12 Y O O O O
Pécs 3597c,h 15 Y Y Y
Tanzaniac, j 16 Y Y Y
545c,h 17 Y Y Y
2017c,h 19 Y O O O O
Ban˜o 36c,k 21 Y O O O O
MEW 22c,g N Y Y Y
C2T0 072605m 1a Y O O O O
Ariel 100101m 1b Y Y O Y
Small Herring 032700m 2 Y Y O Y
C1T1 071204m 2 Y Y O Y
Capelin 071000m 2 Y Y O Y
Large Herring 040700m 2 Y Y O Y
Large Herring 030700m 4 Y Y O Y O
Kri 040201m 5 Y O O O O
C2T0 081004m 5 Y O O O O
Capelin 032200m 5 Y Y O Y
Large Herring 071000m 6 Y O O O O
Large Herring 073100m 6 Y O O Y O
Large Herring 182m 6 Y Y Y Y
A 061101m 8 Y O O O O
Large Herring 072400m 8 Y Y O Y
Orange 120301m 12 Y O O O O
Small Herring 061200m 15 Y O O O O
C2T1 083004m 21 Y Y O Y O
Large Herring 911m 21 Y Y Y Y
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Table 1 (Continued )
Strain Serotype ERY1F/2R Primer 1/2 spaA2F/R Primer 3/4 ERHU-B6091
Orange 021901m 21 Y Y Y Y
Piquet 10507n Xa Y Y O Y
Quitz 262n [2,15]b Y O O O O
SW50l 8 Y O O O O
Immiayuk 6567o 2 Y Y O Y
Kayavak 7122/7155o 5 Y O O O O
Naluark 10797o Xa Y O O O O
ATCC 43339d,p 7 O
Y positive reaction. O negative reaction.
a None of the classical serotypes.
b Partially identical.
c Serotype reference strain.
d Type strain.
e Vaccine strain.
f Challenge strain.
g R.L. Wood collection, unknown origin.
h R.L. Wood collection, swine origin.
i R.L. Wood collection, ﬁsh origin.
j R.L. Wood collection, bird origin.
k R.L. Wood collection, sheep dip origin.
l R.L. Wood collection, dolphin origin.
m John G. Shedd Aquarium collection, ﬁsh origin.
n John G. Shedd Aquarium collection, Paciﬁc white-sided dolphin origin.
o John G. Shedd Aquarium collection, Beluga whale origin.
p R.L. Wood collection, E. tonsillarum, swine origin.
by Center for Veterinary Biologics Notice 08-11 [24]. A 1:30 dilu-
tion was prepared from the working stock and used to vaccinate a
group of 80 mice with a single subcutaneous 0.2mL dose. Fifteen
days after vaccination, a cross-protection study was performed per
E. rhusiopathiae strain by challenging groups of 10–12 vaccinated
mice. Groups of 10 nonvaccinated mice were used as controls and
to calculate LD50 per strain.Micewere housed in isolation and clini-
cal signs and mortality were observed for 10 days. Challenge doses,
given subcutaneously in 0.1mL, were E1-6P, 1,242 LD50; Piquet,
749 LD50; Immiayuk, 425 LD50; Quitz, 316 LD50; Naluark, 262 LD50;
Kayavak, 425 LD50; and Large Herring 182, 368 LD50.
2.9. Statistical methods
Live-versus-dead numbers in the cross-protection studies were
compared by the Fisher exact test using a two-tailed P-value [25].
3. Results
3.1. Polymerase chain reaction
Polymerase chain reaction (PCR) was performed using primers
to detect whole spaA, whole spaB and spaC, and the protective
domain of spaA in 83 E. rhusiopathiae strains (Table 1). Using
primers 1/2 and spaA2/F, designed to amplify whole spaA and the
protective domain of spaA, respectively, all R.L. Wood strains of
serotypes 1a, 1b, 2, 9, 15, 16, 17, and N produced ampliﬁcation
products of appropriate size. Only half of the strains representing
serotypes 5, 8, and 12 produced amplicons with both spaA-speciﬁc
primer sets. There was no gene ampliﬁcation detected in the R.
L. Wood strains of serotypes 4, 6, 11, 19, and 21 with either spaA
primer set.
Production of ampliﬁcation products with both spaA-speciﬁc
primer setswas variable inﬁshand cetacean strains of all serotypes.
Only strains of serotypes 1b and 2 consistently produced ampli-
ﬁcation products of expected size with both primers, while only
ﬁve of 11 ﬁsh strains representing the serotypes 5, 6, 8, and
21 produced ampliﬁcation products. Single strains of serotypes 4
and 21 produced an ampliﬁcation product with the whole spaA
primers, but a product was not produced with the spaA protec-
tive domain primers. Three ﬁsh strains representing serotype 1a,
12, and 15, respectively, failed to produce an amplicon with either
spaA-speciﬁcprimer set.Only twoof six cetacean strains, a serotype
2 Beluga whale strain and a nontypeable dolphin strain, produced
ampliﬁcation products of expected size with both spaA-speciﬁc
primer sets.
Primers3/4, designed toamplifywhole spaBand spaC,wereused
to detect those genes from all E. rhusiopathiae ﬁsh and cetacean
strains, as well as R.L. Wood strains which did not react with
the spaA-speciﬁc primers. Six of seven ﬁsh strains representing
serotypes 4, 6, and 21 produced an amplicon of approximately
1880bp with the primer set. No ampliﬁcation product was pro-
duced from any cetacean strain or strains from the R.L. Wood
collection using the spaB/C-speciﬁc primer set.
A PCR assay utilizing the E. rhusiopathiae species-speciﬁc
primers, ERY1F/2R, was used to verify the species of strains non-
reactive with any of the spa-speciﬁc primers. An amplicon 2210bp
in length was produced from each strain, conﬁrming that these
strains were E. rhusiopathiae.
3.2. Protective domain sequence comparison
The protective domain of spaA was ampliﬁed by PCR from ﬁve
E. rhusiopathiae strains: swine strain E1-6P (serotype 1a); Beluga
whale strain Immiayuk (serotype 2); a nontypeable Paciﬁc white-
sided dolphin strain Piquet; and two ﬁsh strains, Large Herring 182
(serotype 6) and Large Herring 911 (serotype 21). Alignment of the
ﬁve deduced amino acid sequences found that the 342 amino acids
of the protective region ranged from 98.0% to 99.7% identical to the
SpaA protective domain sequence of strain Fujisawa (AB019124);
98.5–99.7% identical to the SpaA protective domain sequence of
strain SE-9 (AB024084); 51.7–52.8% identical to the SpaB pro-
tective domain sequence of strain Dolphin E-1 (AB238212); and
56.7–57.0% identical to the SpaC protective domain sequence of
strain 715 (AB238210).
3.3. Expression of spa and reactivity to a SpaA-speciﬁc
monoclonal antibody
All 83 E. rhusiopathiae strains were examined by SDS-PAGE for
their expression of a 64–66kDa protein and its interaction with the
SpaA-speciﬁc monoclonal antibody, ERHU-B60-91. In SDS-PAGE
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Table 2
Mouse LD50 of E. rhusiopathiae challenge strains.
Strain CFU per challenge LD50 dose Strain origin Serotype
Piquet 2.5×102 7.875 Paciﬁc white-sided dolphin Xa
Immiayuk 2.7×102 7.629 Beluga whale 2
Quitz 4.0×102 7.5 Paciﬁc white-sided dolphin [2,15]b
Naluark 3.1×102 7.419 Beluga whale Xa
Kayavak 2.3×102 7.629 Beluga whale 5
Large Herring 182 2.1×102 7.567 Herring ﬁsh 6
Large Herring 911 3.76×107 –c Herring ﬁsh 21
E1-6P 9.12×102 8.094 Swine 1a
a None of the classical serotypes.
b Partially identical.
c No pathogenicity in mice, strain not used in vaccination-challenge study.
analysis, all 83 strainsproduceda64–66kDaprotein;however, only
those strainswhichproducedanamplicon inPCRwith the spaApro-
tective domain primers, spaA2F/R, produced a protein recognizable
by ERHU-B60-91 (Table 1).
3.4. Strain lethality testing
Pathogenicity data for each strain are listed in Table 2. The
swine, ﬁsh, and cetacean strains appeared nearly equal in their
pathogenicity inmice except for strain Large Herring 911 (serotype
21), which at a dose of 3.76×107 colony forming units (CFU), did
not kill mice.
3.5. Cross-protection experiment
The experimentwas designed to examinewhether the standard
reference bacterin IRP 529(05), composed of the E. rhusiopathiae
serotype 2 SpaA-type strain SE-9, could protect mice equally
against challenge with cetacean and ﬁsh strains of various Spa-
types compared to the serotype 1a SpaA-type swine strain, E1-6P
(Fig. 1).
Within four days after challenge with E1-6P, all nonvaccinated
control mice died while all vaccinated mice survived 10 days
when the experiment was terminated. The difference between
the vaccinated group and the nonvaccinated group was signiﬁcant
(P<0.0001).
Bacterin IRP 529(05) induced complete protection (100%)
against challenge with the SpaA-type dolphin strain Piquet (nonty-
peable) and the SpaA-typeBelugawhale strain Immiayuk (serotype
2). No signiﬁcant difference was exhibited in the ability of the bac-
terin to protect mice against Piquet and Immiayuk compared to
the E1-6P challenge (P=1.0000). Of 12 vaccinated mice challenged
with the SpaA-type Large Herring 182 (serotype 6), only two sur-
Fig. 1. Percentage of immunized mice that survived challenge with E. rhusiopathiae
challenge strains E1-6P, Piquet 10507, Immiayuk 6567, Quitz 262, Naluark 10797,
Kayavak 7122/7155, and Large Herring 182.
vived, indicating a signiﬁcant difference compared to the results of
the E1-6P challenge (P<0.0001).
Upon challenge with the non-SpaA Beluga whale strain Nalu-
ark (nontypeable), seven of 10 vaccinatedmice survived, indicating
that partial protection was induced compared to the E1-6P chal-
lenge (P=0.2105). The ability of the reference bacterin to protect
against challengewith theothernon-SpaA-typestrains showedsig-
niﬁcant differences compared to the E1-6P challenge. Four of 10
vaccinatedmice challengedwith the dolphin strain Quitz (serotype
2, 15) survived (P=0.0108) while none of the 12 vaccinated mice
challenged with the Beluga whale strain Kayavak (serotype 5) sur-
vived (P<0.0001).
4. Discussion
The Spa proteins of E. rhusiopathiae are cell membrane-bound
[12–14,16–18] and recognized as the major protective antigen of
the species [15]. This present study investigated a wide range of E.
rhusiopathiae strains and found that (i) spa-type is not conﬁned to
speciﬁc serotype groups, especially in those strains isolated from
aquatic animals; (ii) a single E. rhusiopathiae strain may possess
more than one spa-type; (iii) the degree of cross-protection elicited
byconventional erysipelasbacterins isdependenton theSpa-status
of the E. rhusiopathiae challenge strain.
Recently, To and Nagai [17] reported the detection of two
additional Erysipelothrix Spa-types, SpaB and SpaC. Based on the
Spa-type observed in single reference strains, they reported that
serotypes 1a, 1b, 2, 5, 8, 9, 12, 15, 16, 17 and N possess spaA;
serotypes 4, 6, 11, 19 and 21 possess spaB; and the unclassiﬁed
serotype 18 possesses spaC. However, earlier reports by bothWood
et al. [7] and Takahashi et al. [6] conﬂict with this organization in
that mice vaccinated with an E. rhusiopathiae serotype 2 (presum-
ably SpaA) strain were variably protected against certain serotypes
currentlywithin the SpaA-group, and completely protected against
serotypes placed in a heterologous Spa-group. Although, the role of
the 64–66kDa proteinwas not realized at the time of those studies,
and thus not investigated, it is important to consider the role that
Spa-type may have had in those evaluations.
In contrast to previous Spa studies [16,17], this study investi-
gated several strains per serotype. These strains were analyzed by
PCR with primers speciﬁc for whole spaA, the protective domain
of spaA, and whole spaB and spaC. Fourteen strains of serotypes
described as possessing spaA, including, ﬁve swine strains rep-
resenting serotypes 5, 8, and 12; six ﬁsh strains representing
serotypes 1a, 5, 8, 12, and 15; and three cetacean strains represent-
ing serotypes 8, 5, and 2/15, were non-reactive with either set of
spaA-speciﬁc primers. After verifying the species identity of these
14 strains, attemptsweremade toamplify spaBand spaCgeneprod-
ucts by PCR, but those assays also yielded negative results.Western
blot veriﬁed that these 14 strains lacked expression of spaA when
the SpaA protective domain-speciﬁc monoclonal antibody, ERHU-
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B60-91, failed to detect the protein. The inability to detect spaA or
its expression product in these particular strains is contrary to the
observation reported by To andNagai [17]which suggests that spa-
type and serotype are related. In this current study, it appears that
these 14 strains have either acquired nucleotide variation of spaA
or possess a novel spa.
The observation that spa-type and serotype are not associ-
ated was further supported when four ﬁsh strains representing
serotypes 6 and21produced amplicons of correct size in PCRassays
using both spaA-speciﬁc primer sets. Expression of spaA was veri-
ﬁed by Western blotting when each of these four strains produced
an approximately 65kDa protein that was detected by ERHU-B60-
91. In addition, PCR products resulting from ampliﬁcation with the
spaA protective domain primers were sequenced, translated into
amino acid sequences, and aligned with published sequences rep-
resenting each Spa-type. These sequences showed high identity to
the SpaA of both strains Fujisawa and SE-9, demonstrating that E.
rhusiopathiae serotypes 6 and 21 (serotypes previously described
as possessing spaB) can possess and express spaA.
In this study, primers designed to amplify spaB and spaC [17]
were used in PCRwith all strains of serotypes 4, 6, 11, 19, and 21, all
ﬁsh and cetacean strains, as well as strains non-reactive with spaA-
speciﬁc primers. Serotype reference strains previously reported
as producing a product in PCR with these primers [17] failed to
produce an ampliﬁcation product in this study. Great care was
taken to exactly follow the described protocol and several assays
were performed to reproduce the published work, but to no avail.
However, the spaB/C PCR assay did prove successful with six ﬁsh
strains representing serotypes 4, 6, and 21, which produced ampli-
cons of expected size. These results indicate the possibility that
some genetic variation exists between this laboratory’s serotype
reference strains and those possessed by To and Nagai [17], which
prevented the spaB/C primers from annealing effectively.
As of yet, E. rhusiopathiae strains have only been described as
possessing a single spa-type. In this study, three ﬁsh strains repre-
senting serotypes 6 and 21 produced amplicons of expected size in
each of the three spa-speciﬁc PCR assays. Twoother ﬁsh strains rep-
resenting serotypes 4 and 21 produced amplicons with the primer
sets designed to amplify whole spaA and whole spaB and spaC.
Although some cross-reaction is possible due to high sequence
similarity of spas in the N-terminal and C-terminal regions, these
results imply that a single E. rhusiopathiae strain may possess
more than one spa-type. Many more E. rhusiopathiae strains, par-
ticularly recent ﬁeld isolates, must be evaluated to more fully
understand the scope and sequence variability of the spa family of
genes.
Nearly all commercial erysipelas bacterins are formulated with
serotype 2 strains which, in swine, offer cross-protection against
the most frequently isolated serotypes, 1a, 1b, and 2 [1]. In this
study, the only group of E. rhusiopathiae strains that consistently
possessed and expressed a single spa-type were the 33 R.L. Wood
strains (mostly clinical swine isolates and vaccine strains) of
serotypes 1a, 1b, and 2. These strains all produced a correctly sized
ampliﬁcation product with both spaA-speciﬁc primer sets, and
expressed a protein recognized by ERHU-B60-91; demonstrating
that spaA is highly conserved in serotypes most often implicated in
clinical swineerysipelas. Thepossessionandexpressionof ahomol-
ogous spa-type likely explain the high rate of cross-protectiveness
among these three serotypes.
It has been reported by Lacave et al. [10] that an inactivated E.
rhusiopathiae swine vaccine strain of serotype 2 can protect mice
against challenge with dolphin strains of serotypes 1a, 2, 5, 15,
and 21, but only partial protection was exhibited in the long term.
Because the Spa-status of the vaccine strain and the challenge
strains were not reported in the study, the effect of Spa-elicited
cross-protection is unknown. Due to the immunological signiﬁ-
cance of the Spa family of proteins [15–18,26] and the variable
cross-protective nature of the three Spa-types currently recognized
[17], it is necessary to evaluate the ability of an erysipelas bacterin
to protect against diverse E. rhusiopathiae challenge strains. In this
present study, the Spa-type of the E. rhusiopathiae bacterin strain
and challenge strains were investigated prior to testing in mice.
Considering To and Nagai’s prior cross-protection study [17], it
was not surprising that vaccinatedmicewere completely protected
against challenge strains possessing a single homologous SpaA and
variably protected against those strains with a heterologous Spa-
type. However, it was interesting that protection against Large
Herring 182, a serotype 21 ﬁsh strain possessing and expressing
spaA and possessing at least one other spa-type, was incomplete;
only 17% of the vaccinated mice survived challenge against Large
Herring 182. This result suggests that antibody to SpaA is not sufﬁ-
cient to protect against an E. rhusiopathiae strain that co-expresses
another spa-type. In this study, the spa-typeobserved inmarineani-
mal E. rhusiopathiae isolates was more variable than expected, and
may be contributing to the incomplete protection seen in cetaceans
vaccinated with commercial swine erysipelas bacterins.
Outbreaks of erysipelas have recently been reported in the
Midwestern United States among vaccinated and nonvaccinated
swine [2]. Although the outbreaks in these cases were ultimately
attributed to inappropriate vaccine management, the variable
cross-protective nature of the Spa proteins may reveal the cause
of some vaccines’ failure to protect. In future erysipelas cases, a
comparison of the spa-type(s) of the vaccine and challenge strains
should be conducted.
The serotype classiﬁcation of Erysipelothrix is based on soluble
peptidoglycan antigens of the cell surface [1], and without interna-
tional guidelines, serotyping results are often inconsistent among
laboratories [14]. Molecular-based systems are proving to be a
more efﬁcient and reliable method of organizing E. rhusiopathiae
strains [5] and assimilation to a new system is anticipated. Because
of their signiﬁcance, a new classiﬁcation scheme based on spa may
be a worthwhile approach.
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